Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC

This study is looking at outcomes for patients with advanced liver cancer (hepatocellular carcinoma, HCC) who have lymph node spread, to better understand how regional lymph node metastasis affects survival when treated with immunotherapy and anti-blood vessel drugs. **You may be eligible if...** - You have been diagnosed with HCC confirmed by imaging, biopsy, or cell testing - Your cancer is classified as advanced-stage (BCLC stage C) with spread outside the liver - You have not received prior systemic (whole-body) treatment for HCC - You are being treated with PD-1/PD-L1 immunotherapy drugs plus anti-angiogenesis drugs - You also received TACE (a procedure delivering chemotherapy directly to the liver tumor) near the time of starting systemic treatment **You may NOT be eligible if...** - You have received prior systemic chemotherapy or targeted therapy for HCC - You did not receive the required combination of treatments Talk to your doctor to see if this trial is right for you.